Pell Bio-Med Technology Co., Ltd.
TAI: 6949.TW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheng Long Lin
- Employees
- 94
- Headquarters
- Taipei, Taiwan
- IPO year
- 2024
- Market cap
- NT$44.8B
- Website
- https://www.pellbmt.com
Loading 6949…
Loading profile data…Frequently asked questions about 6949
What does Pell Bio-Med Technology Co., Ltd. (6949.TW) do?
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company...
Where does 6949.TW trade?
Pell Bio-Med Technology Co., Ltd. (6949.TW) trades on the Taiwan Stock Exchange.
What sector is 6949.TW in?
Pell Bio-Med Technology Co., Ltd. (6949.TW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pell Bio-Med Technology Co., Ltd.?
Cheng Long Lin is the chief executive officer of Pell Bio-Med Technology Co., Ltd. (6949.TW).
Where is Pell Bio-Med Technology Co., Ltd. headquartered?
Pell Bio-Med Technology Co., Ltd. is headquartered in Taiwan.
Does 6949.TW pay a dividend?
Pell Bio-Med Technology Co., Ltd. (6949.TW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6949.TW go public?
Pell Bio-Med Technology Co., Ltd. (6949.TW) completed its initial public offering in 2024.